Abstract
Long-chain acylcarnitines (LCACs) are metabolites essential for lipid metabolism in the heart. Recent metabolomic studies have revealed that high plasma levels of LCACs, especially the 18:1 species, are associated with increased risk of cardiovascular diseases, including atrial arrhythmias.
This study aimed to address whether LCAC 18:1 directly alters the susceptibility for arrhythmias and contractility of human heart muscle.